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Use of Trastuzumab for Metastatic
Breast Cancer in Australia:
Interpreting Findings From a Cohort
of 1,469 Women on a National Access
Program Versus 41 Women Treated
by Two Medical Oncologists
IN REPLY: Wewelcome the opportunity to respond to the letter
byArleneChanandRicharddeBoer and indoing so, demonstrate the
validity of our conclusions regarding the evaluation of trastuzumab
use under a special access programduring the period fromDecember
2001 to March 2005.1 The authors suggest that we have significantly
underestimated the level of cardiacmonitoring andoverestimated the
level of “off-label” trastuzumab use. They also question our interpre-
tationof thefindings in relation to the longerdurationof trastuzumab
therapy in actual practice versus that observed on trial.
With respect to cardiac monitoring, we estimated 158 women
receivedcardiacmonitoring(at leastoneechocardiogramormultiple-
gatedacqusition scan)30daysprior to theirfirst courseof trastuzumab
therapy and 378 (not 47 as quoted by Chan and de Boer) received
cardiac monitoring during their first course of trastuzumab therapy.
Forty-seven of these women were monitored before and during ther-
apy. Drs Chan and de Boer challenge our estimates on the basis of
their clinic data that identified “at least 55 women treated with
trastuzumab-based therapy formetastaticdisease”andreport that “all
patients underwent regular cardiac monitoring.” Further, in a cohort
of 41 patients, they report an average of five episodes of cardiacmon-
itoring during trastuzumab treatment.
It is disappointing to see the authors have failed to describe their
patient cohort and, in particular, whether or not trastuzumab was
supplied under the Herceptin Program. Clearly, the mechanism of
drug supply, for instance in the context of a clinical trial, will influence
monitoring practices. Furthermore, their observation time frame is
longer than inourevaluation(they includeanadditional11monthsof
data before the commencement of the program in December 2001
and an additional 9months at the end of 2005), and for these reasons,
we cannot be certain the authors’ cohort is part of our data set. If,
however, their 41 patients were treated on the Herceptin Program
during the period of our study, they are almost certainly included in
the cohort of 378 individuals we identified as receiving cardiacmoni-
toring during trastuzumab therapy. A caveat to this assumption is the
implausible possibility that the patients treated by Drs Chan and de
Boerspaid the full costof cardiac testsoutof theirownpockets,despite
the fact the tests are fully subsidized by the government. Another
possibility is that all patients treated byDrs Chan and de Boer were so
sick they required hospitalization and received cardiac monitoring
only during admissions to public hospitals. Since our data were ob-
tained fromMedicare Australia, the federal body responsible for sub-
sidizing servicesperformed in thecommunity,wedidnotcapture tests
performed on inpatients in public hospitals. However, by conducting
a validation exercise, we showed that the omission of these data had
little impact on our estimates.
Based on a series of weak premises, the authors assume we have
significantlyunderestimated the level of cardiacmonitoring andmake
theirmostflawedassumption—their practiceswouldnotdeviate sub-
stantially from other Australian oncologists. A plethora of litera-
ture attests to the wide variation in physicians’ prescribing and test
ordering practices,2-11 and our analysis of cardiac monitoring ac-
cording to geographic location also confirms this variability (data
not included).
Drs Chan and de Boer arguewe have overestimated the extent of
off-label trastuzumab use based on an incorrect assumption that we
considered the use of taxanes, platinum, and trastuzumab as off-label.
In fact, we adopted a very conservative approach to the definition of
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off-label use.As stated inourmethods, patients receiving trastuzumab
off-label were registered in the program as receiving monotherapy,
but had at least twodispensing records for taxaneornontaxane chem-
otherapy, or were registered as receiving trastuzumab with taxanes
and had at least two dispensing records for second-line nontaxane
therapy. As such, enrollees commencing trastuzumab therapy with
taxanes and a platinum compound were not included in our off-label
estimates. Furthermore, we did not present the full extent of off-label
use as we did not include the use of trastuzumab with single-agent
cyclophosphamide, fluorouracil, gemcitabine, capecitabine, and vin-
cristine in our estimates. If these drugswere included, the off-label use
increases to 25%.
Finally, the authors question one of our interpretations of the
finding that there was a longer median duration of therapy in the
real-world clinical practice compared with the original trial evidence.
The authors cite two recent trials12,13 with outcomes more closely
approximating our real-world estimates. Interestingly, patients in
these trials had more stringent inclusion criteria (restricting entry to
womenwith immunohistochemical staining3and/orfluorescent in
situ hybridization–positive disease) than those in the original Slamon
et al study (2 or 3 on IHC),14 and these more stringent criteria
mirror exactly, the requirement for enrollment on theHerceptin Pro-
gram. As per our comments in the published article, “the longer
duration of therapy in clinical practice may reflect a greater benefit of
trastuzumab, perhaps because of betterHER-2 target identification.”1
Based on the evidence from the two recent trials, it is possible that the
variationbetweenour studyfindings and thoseof theSlamonet al trial
can be attributed to better target identification. However, we cannot
totallydiscount thehypothesis that the longerduration reflects “reluc-
tance on the part of physicians and patients to cease a drug viewed as
doing no harm.”1 Furthermore, Drs Chan and de Boer have either
discounted or failed to acknowledge our primary point around this
issue, which is that the duration and cost of therapy impacts its cost-
effectiveness. While off-label trastuzumab use may offer a clinical
benefit, this doesnot imply this treatment strategy is cost-effective and
hence affordable.
Monitoring the use of drugs in the real-world setting is crucial,
but accurate conclusions can only be drawn by using unbiased data
sets. Drs Chan and de Boer base their arguments on the un-
founded belief that all doctors practice as they do, and that their
data on “at least 50 women” are superior to data collected from
nearly 1,500 individuals.
Sallie-Anne Pearson, Clare L. Ringland,
and Robyn L. Ward
University of New South Wales, Prince of Wales Hospital, Sydney, Australia
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Does Psychotherapy Affect the
Survival of Cancer Patients?
More Questions Than Answers
TO THE EDITOR: We read with great interest the article by
Ku¨chler et al1 about the impact of psychotherapyon survival of cancer
patients undergoing GI surgery. This report, which was broadly dis-
cussed in the German press, suggests that psychotherapeutic support
may lead to a long-term improvedoutcomeof patientswithGI cancer
undergoing surgery. However, we believed that the results of the trial
might have been affected by a randomization bias. Although the sta-
tistical analysis did not show differences in the composition of the
experimental and control groups with respect to site of tumor, TNM
staging, or residual tumor classification (RTC), there was a substan-
tial difference between both groups regarding the result of surgical
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